GSK’s Shingrix showed to offer ten years of shingles protection in study

GSK has reported positive interim data from the ZOSTER-049 extension study, where its recombinant, adjuvanted Zoster vaccine, Shingrix, showed to offer a minimum of ten years of protection against shingles (herpes zoster) following preliminary vaccination.